Compare LXFR & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXFR | MYGN |
|---|---|---|
| Founded | 1898 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.4M | 481.6M |
| IPO Year | 2002 | 1996 |
| Metric | LXFR | MYGN |
|---|---|---|
| Price | $11.60 | $4.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | 172.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | $384,600,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | $5.01 | $5.64 |
| P/E Ratio | $41.57 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $9.41 | $3.76 |
| 52 Week High | $16.03 | $10.32 |
| Indicator | LXFR | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 23.84 | 41.35 |
| Support Level | $11.24 | $3.93 |
| Resistance Level | $12.33 | $5.63 |
| Average True Range (ATR) | 0.58 | 0.42 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 3.52 | 21.43 |
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.